M T Svendsen1,2,3,4, F Andersen1,5, K H Andersen5, A Pottegård6,7, H Johannessen8, S Möller3,4, B August9, S R Feldman1,10, K E Andersen1,2,5. 1. Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark. 2. Centre for Innovative Medical Technology (CIMT), Clinical Institute, University of Southern Denmark, Odense, Denmark. 3. Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark. 4. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 5. Dermatological Investigations Scandinavia, University of Southern Denmark, Odense, Denmark. 6. Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark. 7. Hospital Pharmacy, Odense University Hospital, Odense, Denmark. 8. Research Unit of User Perspectives, Department of Public Health, University of Southern Denmark, Odense, Denmark. 9. LEO Pharma, Ballerup, Denmark. 10. Department of Dermatology (Center for Dermatology Research), Wake Forest School of Medicine, Winston-Salem, NC, U.S.A.
Abstract
BACKGROUND: Adherence to topical psoriasis treatments is low, which leads to unsatisfactory treatment results. Smartphone applications (apps) for patient support exist but their potential to improve adherence has not been systematically evaluated. OBJECTIVES: To evaluate whether a study-specific app improves adherence and reduces psoriasis symptoms compared with standard treatment. METHODS: We conducted a randomized controlled trial (RCT, clinicaltrials.gov registration: NCT02858713). Patients received once-daily medication [calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam] and were randomized to no app (n = 66) or app intervention (n = 68) groups. In total, 122 patients (91%) completed the 22-week follow-up. The primary outcome was adherence, which was defined as medication applied ≥ 80% of days during the treatment period and assessed by a chip integrated into the medication dispenser. Secondary outcomes were psoriasis severity measured by the Lattice System Physician's Global Assessment (LS-PGA) and quality of life, measured using the Dermatology Life Quality Index (DLQI) at all visits. RESULTS: Intention-to-treat analyses using regression was performed. More patients in the intervention group were adherent to Cal/BD cutaneous foam than those in the nonintervention group at week 4 (65% vs. 38%, P = 0·004). The intervention group showed a greater LS-PGA reduction than the nonintervention group at week 4 (mean 1·86 vs. 1·46, P = 0·047). A similar effect was seen at weeks 8 and 26, although it did not reach statistical significance. CONCLUSIONS: This RCT demonstrates that the app improved short-term adherence to Cal/BD cutaneous foam treatment and psoriasis severity.
RCT Entities:
BACKGROUND: Adherence to topical psoriasis treatments is low, which leads to unsatisfactory treatment results. Smartphone applications (apps) for patient support exist but their potential to improve adherence has not been systematically evaluated. OBJECTIVES: To evaluate whether a study-specific app improves adherence and reduces psoriasis symptoms compared with standard treatment. METHODS: We conducted a randomized controlled trial (RCT, clinicaltrials.gov registration: NCT02858713). Patients received once-daily medication [calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam] and were randomized to no app (n = 66) or app intervention (n = 68) groups. In total, 122 patients (91%) completed the 22-week follow-up. The primary outcome was adherence, which was defined as medication applied ≥ 80% of days during the treatment period and assessed by a chip integrated into the medication dispenser. Secondary outcomes were psoriasis severity measured by the Lattice System Physician's Global Assessment (LS-PGA) and quality of life, measured using the Dermatology Life Quality Index (DLQI) at all visits. RESULTS: Intention-to-treat analyses using regression was performed. More patients in the intervention group were adherent to Cal/BD cutaneous foam than those in the nonintervention group at week 4 (65% vs. 38%, P = 0·004). The intervention group showed a greater LS-PGA reduction than the nonintervention group at week 4 (mean 1·86 vs. 1·46, P = 0·047). A similar effect was seen at weeks 8 and 26, although it did not reach statistical significance. CONCLUSIONS: This RCT demonstrates that the app improved short-term adherence to Cal/BD cutaneous foam treatment and psoriasis severity.
Authors: M Rijsbergen; T Niemeyer-van der Kolk; R Rijneveld; J H F M Pinckaers; I Meshcheriakov; J N Bouwes Bavinck; M B A van Doorn; G Hogendoorn; G Feiss; A F Cohen; J Burggraaf; M I E van Poelgeest; R Rissmann Journal: J Eur Acad Dermatol Venereol Date: 2019-09-04 Impact factor: 6.166
Authors: Bart P H Pouls; Johanna E Vriezekolk; Charlotte L Bekker; Annemiek J Linn; Hein A W van Onzenoort; Marcia Vervloet; Sandra van Dulmen; Bart J F van den Bemt Journal: J Med Internet Res Date: 2021-01-08 Impact factor: 5.428
Authors: Bettina Habib; David Buckeridge; Melissa Bustillo; Santiago Nicolas Marquez; Manish Thakur; Thai Tran; Daniala L Weir; Robyn Tamblyn Journal: JAMIA Open Date: 2021-07-31